HIV Negative and HIV Prevention

CID 0702 - Apheresis procedures to obtain leukocytes from HIV negative subjects

  • Question: Samples used as negative control for exploring new methods of activating resting HIV infected cells in laboratory
  • Population: must be HIV negative and > 18 years of age
  • Duration: up to 3 years
  • Contact: Amanda Crooks (919) 843-9564

HPTN 069 NEXT PREP: Novel Exploration of Therapeutics for PREP: A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC + FTC), Maraviroc + Tenofovir disoproxil fumerate (MVC + TDF), or Tenofovir disoproxil fumerate + Emtricitabine (TDF + FTC) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission in at-Risk Women

  • Population: HIV-uninfected at-risk MSM and at-risk women recruited from sites in the US
  • Medication: maraviroc (MVC) 300 mg, emtricitabine (FTC) 200 mg, tenofovir disoproxil fumerate (TDF) 300 mg, and matching placebos
  • Duration: 1 year
  • Contact: Donna Pittard 919-843-6512

HPTN 073 Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence among Black Men who have Sex with Men (BMSM) in Three U.S. Cities

  • Question: To see how willing Black men who have sex with men are to take PrEP and how consistently they are able to take one tablet at approximately the same time during each day of the week, and what that experience is like for them
  • Population: BSMS (black man who has sex with men) aged 18 or older with no prior HIV diagnosis.
  • Medication: Truvada®
  • Duration: 2 years
  • Contact: Noshima Darde-Tabb (919) 843-6937